In tumor models, for example, SLC circuits have been employed to control the release of immune checkpoint inhibitors or cytolytic agents when microbial density was achieved, thereby confining drug activity to the tumor site (Liao et al. 2024). This evidence concerns the gene CCL21 and neoplasm.